We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bristol-Myers Squibb (BMY) Gains But Lags Market: What You Should Know
Read MoreHide Full Article
Bristol-Myers Squibb (BMY - Free Report) closed at $52 in the latest trading session, marking a +1.66% move from the prior day. The stock lagged the S&P 500's daily gain of 2.3%. Meanwhile, the Dow gained 2.5%, and the Nasdaq, a tech-heavy index, added 2.95%.
Prior to today's trading, shares of the biopharmaceutical company had gained 2.26% over the past month. This has lagged the Medical sector's gain of 3.55% and outpaced the S&P 500's gain of 1.21% in that time.
Wall Street will be looking for positivity from BMY as it approaches its next earnings report date. This is expected to be February 4, 2019. The company is expected to report EPS of $0.84, up 23.53% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $5.99 billion, up 9.85% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of $3.87 per share and revenue of $22.58 billion, which would represent changes of +28.57% and +8.68%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for BMY. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 0.04% higher within the past month. BMY is currently a Zacks Rank #1 (Strong Buy).
Investors should also note BMY's current valuation metrics, including its Forward P/E ratio of 13.21. Its industry sports an average Forward P/E of 14.58, so we one might conclude that BMY is trading at a discount comparatively.
It is also worth noting that BMY currently has a PEG ratio of 1.43. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Large Cap Pharmaceuticals was holding an average PEG ratio of 2.01 at yesterday's closing price.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 78, putting it in the top 30% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow BMY in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Bristol-Myers Squibb (BMY) Gains But Lags Market: What You Should Know
Bristol-Myers Squibb (BMY - Free Report) closed at $52 in the latest trading session, marking a +1.66% move from the prior day. The stock lagged the S&P 500's daily gain of 2.3%. Meanwhile, the Dow gained 2.5%, and the Nasdaq, a tech-heavy index, added 2.95%.
Prior to today's trading, shares of the biopharmaceutical company had gained 2.26% over the past month. This has lagged the Medical sector's gain of 3.55% and outpaced the S&P 500's gain of 1.21% in that time.
Wall Street will be looking for positivity from BMY as it approaches its next earnings report date. This is expected to be February 4, 2019. The company is expected to report EPS of $0.84, up 23.53% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $5.99 billion, up 9.85% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of $3.87 per share and revenue of $22.58 billion, which would represent changes of +28.57% and +8.68%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for BMY. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 0.04% higher within the past month. BMY is currently a Zacks Rank #1 (Strong Buy).
Investors should also note BMY's current valuation metrics, including its Forward P/E ratio of 13.21. Its industry sports an average Forward P/E of 14.58, so we one might conclude that BMY is trading at a discount comparatively.
It is also worth noting that BMY currently has a PEG ratio of 1.43. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Large Cap Pharmaceuticals was holding an average PEG ratio of 2.01 at yesterday's closing price.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 78, putting it in the top 30% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow BMY in the coming trading sessions, be sure to utilize Zacks.com.